Carotid artery stiffness progressed faster in patients with JAK2 V617F positive essential thrombocytemia (ET) than in control subjects. Coronary calcium correlated with the Framingham CHD risk only in control subjects. This indicates that JAK2 V617F positive ET acted as a non-classical risk factor for vascular disease.
COBISS.SI-ID: 6959276
The incidence of aging-related disorders may be decreased through strategies influencing the expression of longevity genes. Although numerous approaches have been suggested, no effective, safe, and easily applicable approach is yet available. Efficacy of low-dose fluvastatin and valsartan, separately or in combination, on the expression of the longevity genes in middle-aged males, was assessed. Stored blood samples from 130 apparently healthy middle-aged males treated with fluvastatin (10 mg daily), valsartan (20 mg daily), fluvastatin-valsartan combination (10 and 20 mg, respectively), and placebo (control) were analyzed. They were taken before and after 30 days of treatment and, additionally, five months after treatment discontinuation. The expression of the following longevity genes was assessed: SIRT1, PRKAA, KLOTHO, NFE2L2, mTOR, and NF-kB. Treatment with fluvastatin and valsartan in combination significantly increased the expression of SIRT1 (1.8-fold; p ( 0.0001), PRKAA (1.5-fold; p = 0.262) and KLOTHO (1.7-fold; p ( 0.0001), but not NFE2L2, mTOR and NF-kB. Both fluvastatin and valsartan alone significantly, but to a lesser extent, increased the expression of SIRT1, and did not influence the expression of other genes. Five months after treatment discontinuation, genes expression decreased to the basal levels.
COBISS.SI-ID: 3231867
Baseline lipoprotein(a) and corrected LDL-C levels and their reductions by alirocumab predicted the risk of major adverse cardiovascular events (MACE) after recent acute coronary syndrome (ACS). Lipoprotein(a) lowering by alirocumab is an independent contributor to MACE reduction, which suggests that lipoprotein(a) should be an independent treatment target after ACS.
COBISS.SI-ID: 13931779
Baseline lipoprotein(a) predicted the risk of total cardiovascular events and risk reduction by alirocumab. Lipoprotein(a) lowering contributed independently to cardiovascular event reduction, supporting the concept of lipoprotein(a) as a treatment target after acute coronary syndrome.
COBISS.SI-ID: 34946307
Both moderate-pain and pain-free training modalities were safe and similarly improved walking capacity and health-related quality of life. Conversely, vascular function improvements were associated with only moderate-pain walking.
COBISS.SI-ID: 5988268